Metabolic Dysfunction-associated Steatotic Liver Disease

The central purpose of the Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) SIG (formerly the NAFLD SIG) is to provide a forum to share ideas, foster collaboration and brainstorm together as an academy of basic and translational investigators. Our mission is to study the pathogenesis, diagnosis, natural history and development of therapeutics for metabolic dysfunction-associated steatotic Liver disease. The MASLD SIG sponsors programs at the AASLD Annual Meeting, identifies emerging topics in MASLD, and supports the educational mission of AASLD policy.

SIG Leadership

Chair
Alina M. Allen, MD

Vice Chair
Amreen Dinani, MD, FRCPC

Associate Lead
Jessica Bartholomew, NP

Communication Lead
Pinelopi Manousou, MD, PhD, FRCP

Education Lead
Robert J. Fontana, MD, FAASLD

Trainee Lead
Maria Mironova, MD, MHSc

ELAPP Ex-Officio
Sonnet Aguirre, PA, MS, RDN

ADVHep Ex-Officio
Christine Brichta, MD, MPH

Staff Liaisons
Akuender Dot, MPH
Julie Hoffman, MBA